List of Excipients in Branded Drug XYZAL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Chattem Inc	XYZAL	levocetirizine dihydrochloride	41167-5803	CELLULOSE, MICROCRYSTALLINE
Chattem Inc	XYZAL	levocetirizine dihydrochloride	41167-5803	FD&C RED NO. 40
Chattem Inc	XYZAL	levocetirizine dihydrochloride	41167-5803	HYPROMELLOSE

XYZAL Excipient Strategy and Commercial Opportunities for Levocetirizine

Last updated: September 5, 2026

XYZAL is a mature levocetirizine brand with limited conventional patent protection and substantial generic competition. The strongest commercial opportunities are therefore formulation-led: pediatric liquids, orally disintegrating tablets, chewables, preservative-free products, improved taste systems, and differentiated combination products. Excipient selection must protect dose uniformity, dissolution, palatability, stability, and regulatory simplicity.

What drug and dosage forms does XYZAL contain?

XYZAL contains levocetirizine dihydrochloride, the active enantiomer of cetirizine. In the United States, the principal marketed formats are:

Product	Strength	Dosage form	Commercial status
XYZAL Allergy 24HR	5 mg levocetirizine dihydrochloride	Film-coated tablet	OTC
Levocetirizine oral solution	0.5 mg/mL	Oral solution	Prescription and generic formats
Generic levocetirizine tablets	5 mg	Film-coated tablet	Multiple generic manufacturers
Generic levocetirizine oral solution	0.5 mg/mL	Oral solution	Multiple generic manufacturers

The 5 mg tablet corresponds to the standard adult and adolescent once-daily dose. Pediatric dosing uses lower doses, making liquid formulation performance commercially important. The FDA-approved labeling identifies levocetirizine as an H1 antihistamine indicated for allergic rhinitis and chronic idiopathic urticaria.[1]

What excipients are used in XYZAL tablets?

The branded tablet formulation uses a conventional immediate-release excipient system. The label-listed inactive ingredients include:

• Lactose monohydrate
• Microcrystalline cellulose
• Colloidal silicon dioxide
• Magnesium stearate
• Hypromellose
• Titanium dioxide
• Macrogol 400

The core excipients support direct compression or conventional tablet manufacture. The film coating provides appearance, swallowability, mechanical protection, and light or moisture protection.

This excipient system is technically effective but offers several opportunities for differentiation. Lactose creates a potential suitability issue for consumers seeking lactose-free products. Titanium dioxide faces continuing regulatory scrutiny in some jurisdictions. Magnesium stearate can affect lubrication, powder flow, and dissolution when used at excessive levels. These factors create opportunities for alternative formulations rather than additional value in duplicating the legacy tablet.

What excipients are used in levocetirizine oral solution?

The oral solution uses a water-based excipient platform that includes glycerin, propylene glycol, sodium acetate trihydrate, acetic acid, methylparaben, saccharin sodium, sodium citrate, purified water, and flavoring components, according to product labeling.[2]

The functional roles are:

Excipient category	Primary function
Glycerin and propylene glycol	Solvent, humectant, mouthfeel modifier
Sodium acetate and acetic acid	Buffering and pH control
Sodium citrate	Buffering and ionic control
Methylparaben	Antimicrobial preservation
Saccharin sodium	Sweetening
Flavor	Taste masking
Purified water	Vehicle

Liquid formulations require tighter control of pH, preservative effectiveness, microbial quality, extractables, leachables, and dose-measurement accuracy than standard tablets.

What excipient strategy best supports a new XYZAL product?

The highest-value strategy is to separate the product portfolio into three platforms: a low-cost standard tablet, a premium pediatric liquid, and a rapidly dissolving or chewable solid dose.

Platform 1: Lactose-free immediate-release tablet

A lactose-free tablet could replace lactose monohydrate with mannitol, anhydrous dibasic calcium phosphate, partially pregelatinized starch, or a combination of microcrystalline cellulose and silicified microcrystalline cellulose.

Mannitol has advantages in mouthfeel and low hygroscopicity. It is suitable for chewable and orally disintegrating formats, although its cooling sensation can affect taste. Dibasic calcium phosphate supports robust compression but may create a chalky mouthfeel and can complicate dissolution optimization. Starch-based systems can improve disintegration but may require tighter control of moisture and compression force.

A lactose-free film-coated tablet would have limited differentiation in the adult allergy market unless paired with a clear consumer claim, such as vegetarian suitability, reduced excipient complexity, or improved swallowability.

Platform 2: Pediatric oral solution

The pediatric liquid has the clearest excipient opportunity because taste, dosing accuracy, and caregiver convenience directly affect adherence.

Potential improvements include:

• Lower or zero propylene glycol content
• A preservative-free unit-dose presentation
• Replacement of methylparaben with an alternative preservative system
• Reduced sucrose exposure or a sugar-free formulation
• Improved flavor masking using sweetener and flavor combinations
• A calibrated oral syringe rather than a household teaspoon
• Unit-dose ampoules for travel and contamination control

A sugar-free liquid can use glycerin, sorbitol, xylitol, or a blended polyol system. Sorbitol may cause gastrointestinal effects at higher exposure. Xylitol can improve taste but increases cost and requires careful assessment of tolerability and manufacturing economics.

Preservative-free packaging can be commercially attractive, but it shifts the burden from chemical preservation to container-closure integrity, microbial control, and packaging cost. Unit-dose sterile or nonsterile presentations must be justified by the target market and expected price premium.

Platform 3: Orally disintegrating tablet or chewable tablet

A 2.5 mg or 5 mg orally disintegrating tablet could target children, older adults, travelers, and consumers with difficulty swallowing.

Likely excipients include:

• Mannitol as a bulking agent
• Crospovidone or croscarmellose sodium as a disintegrant
• Low-substituted hydroxypropyl cellulose
• Aspartame, sucralose, acesulfame potassium, or another high-intensity sweetener
• Flavors and taste-masking agents
• Magnesium stearate or sodium stearyl fumarate as lubricant

The main technical risk is bitterness. Levocetirizine is more manageable than many strongly bitter antihistamines, but an ODT has greater oral exposure than a film-coated tablet. Taste masking should be tested in human sensory studies, not inferred from dissolution alone.

An ODT should target rapid disintegration without excessive friability. Packaging may require aluminum-aluminum blister packs or high-barrier cold-form foil because ODTs are often more moisture-sensitive than conventional tablets.

What formulation patents could protect a new XYZAL product?

A reformulated levocetirizine product may be protected through formulation, composition, packaging, or method-of-use claims rather than the active ingredient.

Potential claim categories include:

Claim category	Commercial relevance
Specific ODT composition	Protects excipient ratios and disintegration performance
Taste-masked levocetirizine particles	Protects pediatric and chewable products
Preservative-free liquid	Protects vehicle and container-closure combination
Low-propylene-glycol liquid	Supports pediatric positioning
Unit-dose liquid package	Protects dosing and stability architecture
Modified-release formulation	Could support longer duration, but requires substantial clinical evidence
Combination product	May protect levocetirizine with a decongestant or another allergy agent
Manufacturing process	Can protect particle engineering, granulation, coating, or content uniformity

A broad patent directed only to levocetirizine as an antihistamine would face substantial validity and prior-art risk. A stronger filing would claim a defined technical result, such as rapid disintegration at a specified hardness, acceptable taste scores, preservative-free stability, or a particular impurity profile.

Patent strength would depend on demonstrated unexpected results. A routine substitution of lactose with mannitol is generally weaker than a formulation showing improved stability, dissolution, palatability, and manufacturing performance at the same time.

When does XYZAL lose exclusivity?

XYZAL is a mature product. The original active-ingredient and product exclusivity periods have expired, and generic levocetirizine products are commercially established in the United States.[3]

The practical competitive position is:

Exclusivity element	Current assessment
Active ingredient exclusivity	Expired
Original small-molecule patent protection	Expired or commercially exhausted
FDA regulatory exclusivity	Expired
Generic tablet entry	Established
Generic oral-solution entry	Established
Brand OTC differentiation	Based on brand, packaging, distribution, and consumer marketing
New formulation protection	Available only through separate, defensible inventions

The commercial value of a new patent would come from protecting a differentiated dosage form rather than extending exclusivity for the conventional 5 mg tablet.

What is the Orange Book status of XYZAL?

The Orange Book lists FDA-approved prescription drug products and relevant patent and exclusivity information. The OTC XYZAL brand is not equivalent to an active prescription Orange Book exclusivity position. Prescription levocetirizine products and generic approvals are evaluated through the FDA’s approved-drug databases and product-specific labeling.[3]

Because the core levocetirizine product is genericized, a new applicant would likely pursue one of three routes:

1. An abbreviated new drug application for a conventional equivalent product.
2. A 505(b)(2) application for a differentiated formulation, delivery system, or dosing regimen.
3. An OTC switch or monograph-based strategy, depending on the product’s active ingredient, labeling, dosage form, and regulatory pathway.

A formulation with a new excipient system may still qualify for an ANDA if it is pharmaceutically equivalent, bioequivalent, and otherwise meets FDA requirements. A product that changes route, release profile, clinical use, or dosage regimen may require a 505(b)(2) application.

Which companies are challenging or competing with XYZAL?

Competition comes from both levocetirizine generics and alternative antihistamines.

Competitor	Active ingredient	Main competitive basis
Generic levocetirizine	Levocetirizine	Price and pharmacy substitution
Zyrtec and cetirizine generics	Cetirizine	Broad recognition and low cost
Claritin and loratadine generics	Loratadine	Non-sedating allergy positioning
Allegra and fexofenadine generics	Fexofenadine	Low-sedation positioning
Xyzal Allergy 24HR	Levocetirizine	Brand awareness and OTC distribution

Levocetirizine has a potential sedation disadvantage relative to some competing second-generation antihistamines. A formulation strategy should therefore avoid claims that imply superior alertness unless supported by clinical evidence.

What Paragraph IV challenges and litigation affect XYZAL?

Generic levocetirizine entry has already occurred, so historical Paragraph IV activity is more relevant than current market access risk for the original product. A new formulation would create a new litigation profile if patents are listed or asserted against an ANDA applicant.

For a newly patented product, potential litigation would focus on:

• Whether the generic product practices the formulation claims
• Whether the claims are obvious over cetirizine and levocetirizine prior art
• Whether the product has a different excipient ratio but equivalent performance
• Whether a process patent is infringed by an undisclosed manufacturing route
• Whether the patent is eligible for Orange Book listing
• Whether a Paragraph IV certification triggers a 30-month stay

A formulation patent that cannot be listed in the Orange Book may still be enforceable, but its litigation leverage and launch-blocking effect can be lower. A 505(b)(2) product may face patent certification requirements depending on the listed patents and reference product relationship.

No biologic component exists in XYZAL. Biosimilar risk is therefore not applicable. The relevant competitors are generics, OTC brands, private-label products, and other small-molecule antihistamines.

What generic launch risks exist for a new XYZAL formulation?

The main generic launch risks are high if the product is a conventional tablet and moderate if it uses a technically differentiated dosage form.

Product concept	Generic risk	Main defense
Standard 5 mg tablet	High	Low-cost manufacturing and brand loyalty
Lactose-free tablet	High to moderate	Narrow formulation claims
Chewable tablet	Moderate	Taste-masking and performance patents
ODT	Moderate	Composition, packaging, and disintegration claims
Pediatric liquid	Moderate	Vehicle, preservative, flavor, and packaging claims
Preservative-free unit dose	Moderate to low	Container-closure and stability data
Modified-release product	Lower initially	Clinical and formulation complexity

A generic can often design around a narrow excipient claim by changing the filler, lubricant, sweetener, flavor, or disintegrant. Patent drafting should therefore include multiple formulation embodiments and performance-based claims where support exists.

What commercial opportunities exist for XYZAL excipients?

Pediatric allergy market

Pediatric liquid and chewable products have the strongest commercial logic. Caregivers value accurate dosing, acceptable taste, low sugar, and easy administration. A product priced above generic liquid can succeed if it reduces administration problems and has credible pediatric positioning.

Private-label and contract manufacturing

A standardized levocetirizine excipient platform could support private-label retailers, pharmacy chains, telehealth brands, and international distributors. The opportunity is greatest where the manufacturer can offer multiple flavors, package sizes, and regulatory dossiers from one formulation platform.

Premium adult OTC products

Adult products can target lactose-free, easy-swallow, small-tablet, or rapidly dissolving formats. Premium pricing will be difficult without a visible consumer benefit because generic levocetirizine and cetirizine are widely available.

Excipient and delivery-system licensing

Licensing opportunities may exist for:

• Taste-masked levocetirizine microparticles
• Direct-compression ODT platforms
• Moisture-protective blister systems
• Preservative-free multidose containers
• Low-sugar pediatric liquids
• Flavor systems validated for antihistamines

The most defensible licensing asset is a platform that applies to multiple antihistamines, not a single routine XYZAL reformulation. A technology that also works with cetirizine, loratadine, desloratadine, or fexofenadine can support a broader commercial agreement.

How does XYZAL compare with Zyrtec, Claritin, and Allegra?

Factor	XYZAL	Zyrtec	Claritin	Allegra
Active ingredient	Levocetirizine	Cetirizine	Loratadine	Fexofenadine
Product maturity	Mature	Mature	Mature	Mature
Generic competition	High	High	High	High
Main differentiation	Levocetirizine brand and dosing	Strong consumer recognition	Non-drowsy positioning	Low-sedation positioning
Best formulation opportunity	Pediatric liquid, ODT, chewable	Similar	Similar	Similar
Patent-led growth potential	Limited for legacy tablet	Limited for legacy tablet	Limited for legacy tablet	Limited for legacy tablet

XYZAL does not have a clear molecule-level exclusivity advantage over competing antihistamines. Its opportunity is execution in formulation, packaging, distribution, and consumer positioning.

What is the regulatory status of XYZAL?

FDA-approved levocetirizine products are regulated as small-molecule drug products. The OTC XYZAL product uses nonprescription labeling, while prescription levocetirizine products use prescription labeling and dosage instructions.[1,2]

A new excipient strategy must address:

• FDA inactive-ingredient acceptability
• Daily exposure of each excipient
• Pediatric safety
• Preservative effectiveness
• Assay and degradation products
• Dissolution or disintegration
• Bioequivalence where required
• Container-closure compatibility
• Labeling and dosing-device performance

A new excipient or substantially increased exposure to an existing excipient can increase regulatory burden. The lowest-risk path generally uses established excipients at precedent-supported levels.

Key Takeaways

• XYZAL is a mature levocetirizine product with expired core exclusivity and established generic competition.
• Conventional 5 mg tablets offer limited patent and pricing opportunity.
• Pediatric oral solutions, chewables, ODTs, and preservative-free unit-dose products provide the strongest formulation opportunities.
• Lactose-free and titanium-dioxide-free positioning may support targeted differentiation but is unlikely to create durable value alone.
• Taste masking, dosing accuracy, stability, and packaging are the main technical value drivers.
• Formulation patents should claim defined compositions and demonstrated performance, not routine excipient substitutions.
• The most valuable licensing assets are platform technologies applicable to several antihistamines.
• Biosimilar risk does not apply because levocetirizine is a small molecule.
• Generic launch risk remains high for conventional tablets and moderate for technically differentiated liquids and solid dosage forms.

FAQs

Can levocetirizine be reformulated as an orally disintegrating tablet?

Yes. An ODT can use mannitol, a superdisintegrant, sweeteners, flavors, and moisture-protective packaging. Taste masking and friability are the principal development risks.

Is a lactose-free XYZAL tablet commercially attractive?

It can address a defined consumer segment, but lactose-free status alone is unlikely to support substantial premium pricing. The opportunity improves when combined with smaller tablet size, easier swallowing, or rapid disintegration.

Can a preservative-free levocetirizine liquid be patented?

Yes, if the product has a novel and nonobvious formulation or container-closure system with supporting stability and microbial-control data. A routine preservative deletion is more vulnerable to obviousness challenges.

Would a new levocetirizine liquid require a 505(b)(2) application?

Not necessarily. A pharmaceutically equivalent and bioequivalent liquid may qualify for an ANDA. A materially different formulation, dosing regimen, or clinical positioning may require a 505(b)(2) pathway.

Which XYZAL formulation has the best commercial outlook?

A pediatric, low-sugar, well-tolerated oral liquid with a calibrated syringe and strong taste profile has the clearest opportunity. An ODT or chewable product is the next strongest option, particularly for travel and swallowing convenience.

References

1. U.S. Food and Drug Administration. (2023). Levocetirizine dihydrochloride prescribing information. FDA/DailyMed.

2. National Library of Medicine. (2024). Levocetirizine dihydrochloride oral solution: Drug label information. DailyMed.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.